R R

What Is Risedronate?

Risedronate is a prescription bisphosphonate medication used to treat or prevent certain bone disorders. It is commonly prescribed for osteoporosis in postmenopausal women and men and for bone loss associated with glucocorticoid treatment. Risedronate is also approved to treat Paget's disease of bone. It is available as oral tablets, including formulations associated with the brand names Actonel and Atelvia. Different products have separate administration instructions and dosing schedules. Risedronate reduces bone breakdown and can lower fracture risk in eligible patients. Treatment requires assessment of kidney function, calcium levels, and the ability to follow upright posture requirements.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Risedronate?

Risedronate is a prescription bisphosphonate medication used to treat or prevent certain bone disorders. It is commonly prescribed for osteoporosis in postmenopausal women and men and for bone loss associated with glucocorticoid treatment. Risedronate is also approved to treat Paget's disease of bone. It is available as oral tablets, including formulations associated with the brand names Actonel and Atelvia. Different products have separate administration instructions and dosing schedules. Risedronate reduces bone breakdown and can lower fracture risk in eligible patients. Treatment requires assessment of kidney function, calcium levels, and the ability to follow upright posture requirements.

read more about risedronate ...

Copy this HTML:

Copy HTML Copied!

How Does Risedronate Work?

Risedronate binds to mineralized bone surfaces and is taken up by osteoclasts, the cells responsible for breaking down bone. It inhibits farnesyl pyrophosphate synthase, an enzyme involved in pathways needed for normal osteoclast function. This reduces bone resorption and helps maintain or increase bone mineral density. In osteoporosis, reduced breakdown can lower the risk of certain fractures. In Paget's disease, risedronate helps suppress excessive and disorganized bone remodeling. The medication remains associated with bone tissue after administration, contributing to effects that persist beyond each dose. It does not immediately restore bone already lost from osteoporosis.

What Conditions Does Risedronate Treat?

Risedronate is approved for treatment and prevention of postmenopausal osteoporosis, treatment of osteoporosis in men, and treatment and prevention of glucocorticoid-induced osteoporosis in eligible adults. It is also approved for Paget's disease of bone, a condition involving abnormal bone remodeling that can cause pain, deformity, and other complications. Individual formulations may not share every indication. Risedronate is not recommended for patients with severe kidney impairment and is contraindicated in those with low blood calcium or certain esophageal abnormalities. A clinician evaluates fracture risk, bone density, renal function, and gastrointestinal history before prescribing it.

How Should Risedronate Be Taken?

Risedronate dosing depends on the indication and formulation. Immediate-release treatment for postmenopausal osteoporosis may use 5 mg daily, 35 mg once weekly, or approved monthly regimens. Paget's disease treatment commonly uses 30 mg daily for two months. Immediate-release tablets should be swallowed whole with six to eight ounces of plain water at least 30 minutes before the first food, drink, or other medication of the day. Patients must remain upright for at least 30 minutes afterward. Delayed-release risedronate products have different instructions and are generally taken after breakfast. Calcium supplements and antacids may interfere with absorption and should be separated according to the product label.

What Are the Side Effects and Warnings of Risedronate?

Common adverse effects include abdominal discomfort, nausea, heartburn, joint pain, and muscle pain. Serious risks include esophageal irritation or ulceration, low blood calcium, osteonecrosis of the jaw, and atypical femur fractures. Severe bone, joint, or muscle pain can also occur. Bisphosphonates, including risedronate, have been associated with eye inflammation such as uveitis and scleritis. Improper administration can increase esophageal injury risk, making the upright posture and water instructions important. Patients should report difficulty swallowing, chest pain, persistent heartburn, jaw problems, unusual thigh pain, or new eye pain and redness. Long-term treatment should be periodically reassessed.

Common Questions About Risedronate

Is risedronate the same as Actonel?

Yes. Actonel is a brand name for risedronate sodium. Other formulations, such as Atelvia, have different administration instructions.

Can risedronate treat osteoporosis?

Yes. Risedronate is approved for several osteoporosis-related indications, including postmenopausal osteoporosis and osteoporosis in men.

Why must patients remain upright after taking risedronate?

Remaining upright for at least 30 minutes after immediate-release tablets helps reduce the risk of esophageal irritation and injury.

Can risedronate cause eye inflammation?

Yes. Eye inflammation, including uveitis and scleritis, has been reported with bisphosphonates. Eye pain, redness, or new visual symptoms require prompt evaluation.

References

Bisphosphonates. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548566/. Date Accessed November 3, 2026.

DailyMed - ACTONEL (risedronate sodium) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24ed00e0-25e2-49a8-97fc-66c1b417dc0b. Date Accessed November 3, 2026.

Risedronate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601247.html. Date Accessed November 3, 2026.

Risedronate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Risedronate. Date Accessed November 3, 2026.

Risedronate. IUPHAR/BPS Guide to Pharmacology. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3176. Date Accessed November 3, 2026.